German biotechnology company “BioNTech”, one of the first companies to develop vaccines against the COVID-19 epidemic, has announced that it will pay more attention to cancer research in the coming years.
Publika.az Turkish media reports that “BioNTech” officials announced this at the “JP Morgan” healthcare conference held in San Francisco yesterday. The company presented its strategic priorities and revenue expectations for 2024.
General director and co-founder of “BioNTech” Prof. Dr. Ugur Sahin emphasized that they are currently conducting research in the advanced development stage for various types of cancer and plan to obtain ten or more potential results from the research by the end of 2024.
“This year will be an important year at BioNTech, as we continue to expand and develop our innovative products towards our first oncology applications expected in 2026,” said the Turkish professor.
The company aims to generate around 3 billion euros in revenue this year, mainly from its COVID-19 vaccines.
Biontech has approximately 17.5 billion euros in cash and securities investments by the end of 2023, and the company will continue to invest in research and development despite declining sales of its COVID-19 vaccines, the statement said.
